O	0	11	Circulating
O	12	20	hormones
O	21	24	and
O	25	31	breast
O	32	38	cancer
O	39	43	risk
O	44	46	in
O	47	60	premenopausal
O	61	66	women
O	66	67	:
O	68	69	a
O	70	80	randomized
O	81	86	trial
O	87	89	of
B-intervention	90	93	low
I-intervention	93	94	-
I-intervention	94	98	dose
I-intervention	99	108	tamoxifen
I-intervention	109	112	and
I-intervention	113	124	fenretinide
O	124	125	.

O	126	135	Tamoxifen
O	136	139	and
O	140	151	fenretinide
O	152	156	have
O	157	161	been
O	162	173	extensively
O	174	181	studied
O	182	185	and
O	186	193	exhibit
O	194	200	breast
O	201	207	cancer
O	207	208	-
O	208	218	preventing
O	219	227	activity
O	227	228	.

O	229	231	We
O	232	237	aimed
O	238	240	to
O	241	247	assess
O	248	253	their
O	254	260	effect
O	261	263	on
O	264	267	sex
O	268	276	hormones
O	276	277	,
O	278	281	sex
O	282	289	hormone
O	290	297	binding
O	298	306	globulin
O	307	308	(
O	308	312	SHBG
O	312	313	)
O	314	317	and
O	318	325	retinol
O	325	326	,
O	327	330	and
O	331	336	their
O	337	348	association
O	349	353	with
O	354	366	mammographic
O	367	374	density
O	375	376	(
O	376	378	MD
O	378	379	)
O	380	383	and
O	384	390	breast
O	391	397	cancer
O	398	404	events
O	404	405	.

O	406	408	In
O	409	410	a
O	411	417	double
O	417	418	-
O	418	423	blind
O	423	424	,
O	425	432	placebo
O	432	433	-
O	433	443	controlled
O	444	449	trial
O	449	450	,
O	451	464	premenopausal
O	465	470	women
O	471	473	at
O	474	478	risk
O	479	482	for
O	483	489	breast
O	490	496	cancer
O	497	501	were
O	502	512	randomized
O	513	515	to
O	516	525	tamoxifen
O	526	527	5
O	528	530	mg
O	530	531	/
O	531	534	day
O	534	535	,
O	536	547	fenretinide
O	547	548	,
O	549	553	both
O	554	560	agents
O	560	561	,
O	562	564	or
B-control	565	572	placebo
O	573	576	for
O	577	578	2
O	579	584	years
O	584	585	.

O	586	588	We
O	589	597	measured
O	598	600	MD
O	601	604	and
O	605	616	circulating
O	617	631	concentrations
O	632	634	of
O	635	643	follicle
O	643	644	-
O	644	655	stimulating
O	656	663	hormone
O	663	664	,
O	665	676	luteinizing
O	677	684	hormone
O	685	686	(
O	686	688	LH
O	688	689	)
O	689	690	,
O	691	700	estradiol
O	700	701	,
O	702	714	progesterone
O	714	715	,
O	716	728	testosterone
O	728	729	,
O	730	745	androstenedione
O	745	746	,
O	747	754	dehydro
O	754	755	-
O	755	777	epiandrosteronesulfate
O	777	778	,
O	779	788	prolactin
O	788	789	,
O	790	794	SHBG
O	794	795	,
O	796	799	and
O	800	807	retinol
O	808	810	at
O	811	819	baseline
O	820	823	and
O	824	826	on
O	827	833	yearly
O	834	843	intervals
O	843	844	.

O	845	848	The
O	849	861	associations
O	862	866	with
O	867	873	breast
O	874	880	cancer
O	881	887	events
O	888	892	were
O	893	902	evaluated
O	903	910	through
O	911	920	competing
O	921	925	risk
O	926	929	and
O	930	933	Cox
O	934	944	regression
O	945	953	survival
O	954	960	models
O	960	961	.

O	962	965	Low
O	965	966	-
O	966	970	dose
O	971	980	tamoxifen
O	981	989	markedly
O	990	993	and
O	994	1004	enduringly
O	1005	1014	increased
B-outcome	1015	1019	SHBG
O	1019	1020	,
O	1021	1028	whereas
O	1029	1032	the
O	1033	1042	increases
O	1043	1045	in
B-outcome	1046	1058	testosterone
O	1058	1059	,
B-outcome	1060	1069	estradiol
O	1069	1070	,
O	1071	1074	and
B-outcome	1075	1084	prolactin
O	1085	1088	and
O	1089	1098	reduction
O	1099	1101	in
B-outcome	1102	1104	LH
O	1105	1113	weakened
O	1114	1119	after
O	1120	1121	1
O	1122	1126	year
O	1126	1127	.

O	1128	1139	Fenretinide
O	1140	1149	increased
B-outcome	1150	1162	testosterone
I-outcome	1163	1166	and
I-outcome	1167	1182	androstenedione
O	1183	1186	and
O	1187	1196	decreased
B-outcome	1197	1204	retinol
O	1204	1205	.

O	1206	1208	MD
O	1209	1219	correlated
O	1220	1228	directly
O	1229	1233	with
O	1234	1238	SHBG
O	1239	1242	and
O	1243	1252	inversely
O	1253	1257	with
O	1258	1265	retinol
O	1265	1266	.

O	1267	1272	After
O	1273	1274	a
O	1275	1281	median
O	1282	1288	follow
O	1288	1289	-
O	1289	1291	up
O	1292	1294	of
O	1295	1297	12
O	1298	1303	years
O	1303	1304	,
O	1305	1308	the
B-outcome	1309	1311	10
I-outcome	1311	1312	-
I-outcome	1312	1316	year
I-outcome	1317	1327	cumulative
I-outcome	1328	1337	incidence
I-outcome	1338	1340	of
I-outcome	1341	1347	breast
I-outcome	1348	1354	cancer
I-outcome	1355	1361	events
O	1362	1365	was
O	1366	1368	37
O	1369	1370	%
O	1371	1373	in
O	1374	1379	women
O	1380	1384	with
O	1385	1389	SHBG
O	1390	1391	â
O	1391	1392	‰
O	1392	1393	¤
O	1394	1396	59
O	1396	1397	.
O	1397	1398	3
O	1399	1403	nmol
O	1403	1404	/
O	1404	1405	L
O	1405	1406	,
O	1407	1409	22
O	1410	1411	%
O	1412	1414	in
O	1415	1420	women
O	1421	1425	with
O	1426	1430	SHBG
O	1431	1438	between
O	1439	1441	59
O	1441	1442	.
O	1442	1443	3
O	1444	1447	and
O	1448	1451	101
O	1452	1456	nmol
O	1456	1457	/
O	1457	1458	L
O	1458	1459	,
O	1460	1463	and
O	1464	1466	19
O	1467	1468	%
O	1469	1471	in
O	1472	1477	women
O	1478	1482	with
O	1483	1487	SHBG
O	1488	1489	>
O	1490	1493	101
O	1494	1498	nmol
O	1498	1499	/
O	1499	1500	L
O	1501	1502	(
O	1502	1503	P
O	1504	1505	=
O	1506	1507	0
O	1507	1508	.
O	1508	1511	018
O	1511	1512	)
O	1512	1513	.

O	1514	1517	The
O	1518	1528	difference
O	1529	1534	among
O	1535	1539	SHBG
O	1540	1548	tertiles
O	1549	1557	remained
O	1558	1571	statistically
O	1572	1583	significant
O	1584	1586	at
O	1587	1600	multivariable
O	1601	1609	analysis
O	1609	1610	:
O	1611	1613	HR
O	1614	1615	=
O	1616	1617	2
O	1617	1618	.
O	1618	1620	26
O	1621	1622	(
O	1622	1624	95
O	1625	1626	%
O	1627	1629	CI
O	1630	1631	1
O	1631	1632	.
O	1632	1634	04
O	1634	1635	,
O	1636	1637	4
O	1637	1638	.
O	1638	1640	89
O	1640	1641	)
O	1642	1645	for
O	1646	1649	the
O	1650	1656	lowest
O	1657	1663	versus
O	1664	1667	the
O	1668	1675	highest
O	1676	1683	tertile
O	1683	1684	.

O	1685	1687	We
O	1688	1696	conclude
O	1697	1701	that
O	1702	1705	low
O	1705	1706	-
O	1706	1710	dose
O	1711	1720	tamoxifen
O	1721	1723	or
O	1724	1735	fenretinide
O	1736	1744	exhibits
O	1745	1754	favorable
O	1755	1763	hormonal
O	1764	1772	profiles
O	1773	1775	as
O	1776	1782	single
O	1783	1789	agents
O	1789	1790	,
O	1791	1798	further
O	1799	1809	supporting
O	1810	1815	their
O	1816	1830	administration
O	1831	1834	for
O	1835	1845	prevention
O	1846	1848	of
O	1849	1855	breast
O	1856	1862	cancer
O	1863	1865	in
O	1866	1878	premenopause
O	1878	1879	.

O	1880	1887	Notably
O	1887	1888	,
O	1889	1893	SHBG
O	1894	1900	levels
O	1901	1905	were
O	1906	1915	inversely
O	1916	1926	associated
O	1927	1931	with
O	1932	1938	breast
O	1939	1949	neoplastic
O	1950	1956	events
O	1956	1957	.
